CenterBook Partners LP Has $2.43 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Key Points

• CenterBook Partners LP increased its stake in Humacyte, Inc. by 11.1%, owning approximately 1,422,512 shares valued at $2.43 million.
• Humacyte's stock is currently trading at $2.21, down 4.3%, with a market cap of about $342.82 million and a price-to-earnings ratio of -3.20.
• Recent earnings results showed EPS of ($0.10), exceeding estimates, with analysts projecting an EPS of -1.27 for the current fiscal year.

CenterBook Partners LP boosted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 11.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,422,512 shares of the company's stock after buying an additional 142,673 shares during the quarter. CenterBook Partners LP owned about 0.92% of Humacyte worth $2,425,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Woodline Partners LP lifted its holdings in Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after purchasing an additional 2,000,268 shares during the last quarter. Brevan Howard Capital Management LP grew its stake in Humacyte by 2,795.1% in the 4th quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company's stock valued at $4,426,000 after buying an additional 846,070 shares during the last quarter. Vanguard Group Inc. raised its holdings in Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after acquiring an additional 543,995 shares during the period. Franklin Resources Inc. acquired a new position in Humacyte during the 4th quarter worth $2,189,000. Finally, Bank of America Corp DE grew its position in shares of Humacyte by 160.2% in the fourth quarter. Bank of America Corp DE now owns 597,319 shares of the company's stock valued at $3,016,000 after purchasing an additional 367,720 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Humacyte Stock Down 4.3%

Shares of HUMA opened at $2.21 on Thursday. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average price of $2.41 and a two-hundred day moving average price of $2.59. The stock has a market cap of $342.82 million, a price-to-earnings ratio of -3.20 and a beta of 1.90. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $8.72.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.46 million. Equities analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on HUMA shares. Wall Street Zen cut Humacyte from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Wednesday, July 23rd. HC Wainwright initiated coverage on shares of Humacyte in a report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective on the stock. Finally, Benchmark reduced their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Want to see what other hedge funds are holding HUMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.